- Home
- AKBA vs GILT Comparison
AKBA vs GILT Comparison
Compare AKBA & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- GILT
- Stock Information
- Founded
- AKBA 2007
- GILT 1987
- Country
- AKBA United States
- GILT Israel
- Employees
- AKBA N/A
- GILT N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- GILT Radio And Television Broadcasting And Communications Equipment
- Sector
- AKBA Health Care
- GILT Technology
- Exchange
- AKBA Nasdaq
- GILT Nasdaq
- Market Cap
- AKBA 336.2M
- GILT 347.8M
- IPO Year
- AKBA 2014
- GILT 1993
- Fundamental
- Price
- AKBA $2.37
- GILT $7.01
- Analyst Decision
- AKBA Strong Buy
- GILT Strong Buy
- Analyst Count
- AKBA 1
- GILT 2
- Target Price
- AKBA $7.50
- GILT $8.50
- AVG Volume (30 Days)
- AKBA 2.4M
- GILT 375.3K
- Earning Date
- AKBA 03-13-2025
- GILT 02-24-2025
- Dividend Yield
- AKBA N/A
- GILT N/A
- EPS Growth
- AKBA N/A
- GILT 17.04
- EPS
- AKBA N/A
- GILT 0.29
- Revenue
- AKBA $169,879,000.00
- GILT $302,932,000.00
- Revenue This Year
- AKBA N/A
- GILT $18.64
- Revenue Next Year
- AKBA $30.85
- GILT $32.62
- P/E Ratio
- AKBA N/A
- GILT $22.98
- Revenue Growth
- AKBA N/A
- GILT 15.14
- 52 Week Low
- AKBA $0.80
- GILT $4.04
- 52 Week High
- AKBA $2.48
- GILT $7.18
- Technical
- Relative Strength Index (RSI)
- AKBA 75.15
- GILT 73.07
- Support Level
- AKBA $1.72
- GILT $6.50
- Resistance Level
- AKBA $2.00
- GILT $6.77
- Average True Range (ATR)
- AKBA 0.11
- GILT 0.27
- MACD
- AKBA 0.04
- GILT 0.05
- Stochastic Oscillator
- AKBA 100.00
- GILT 86.72
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs) and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.